Abstract
Recent technical advances have begun to realize the potential of molecular beacons to test for diverse infections in clinical diagnostic laboratories. These include the ability to test for, and quantify, multiple pathogens in the same clinical sample, and to detect antibiotic resistant strains within hours. The design principles of molecular beacons have also spawned a variety of allied technologies.

Introduction
Imagine a magic reagent to which is added a droplet of body fluid from a patient. A glow appears in the tube and the color of the glow identifies the pathogen responsible for the patient’s illness. Such was the promise of molecular beacons when they were first introduced 15 years ago [1]. That promise is now bearing fruit, as powerful new tests for diverse infections are being introduced into clinical diagnostic laboratories.

Molecular beacons are hairpin-shaped oligonucleotide probes that become fluorescent upon hybridization to an RNA or DNA target sequence. Their loops serve as probes and are about 15 to 25 nucleotides long. Their stems serve to bring the two ends of the molecule, which are linked to a fluorophore and a quencher, into close proximity. Although the stems are only 5 to 7 nucleotides long, they keep the labels in close proximity so that the fluorescence of the fluorophore is quenched in the free probes. However, upon binding to their target, they undergo a spontaneous conformational reorganization that removes the fluorophore from the vicinity of the quencher and restores its fluorescence (Figure 1). Molecular beacons specific for different target sequences and labeled with differently colored fluorophores can be used together to simultaneously identify and quantitate multiple targets in the same assay tube [2].

Given this fluorogenic response, the addition of the probes to nucleic acids isolated from a clinical sample containing a relatively large number of infectious agents would be sufficient to generate a detectable signal. However, human clinical samples contain only miniscule amounts of pathogen-derived nucleic acids. It is therefore necessary to first amplify an identifying target sequence from the pathogen’s nucleic acid. In a typical assay, nucleic acids are extracted from the sample, and a segment of the pathogen’s genome (containing the target sequence) is amplified in a polymerase chain reaction (PCR), or in a nucleic acid sequence-based amplification (NASBA) reaction, while simultaneously monitoring the fluorescence of the target-specific molecular beacons in the reaction mixture [1-3]. Since fluorescence is measured in sealed tubes, carryover contamination, which plagued earlier assays, cannot occur. Moreover, the measurement of fluorescence is in real time, as opposed to making measurements at end points, which enables quantitation over an extremely wide dynamic range of target concentrations [4].

Recent advances
Soon after the introduction of molecular beacons and other target-specific fluorogenic probes, such as TaqMan probes [1,5], spectrofluorometric thermal cyclers became available that could perform PCR assays while simultaneously monitoring fluorescence changes. In addition, automated nucleic acid extraction protocols were
introduced. With the availability of these resources, the development of nucleic acid-based assays for pathogens became relatively simple, and there are now a large number of tests available for the detection of human pathogens, and food and environmental contaminants (Table 1).

Most of the assays listed in the table are designed to detect an individual pathogenic species. However, it is often desirable to determine the type of pathogens that are present in a clinical sample, for example, does the sample contain Gram-negative bacteria, Gram-positive bacteria, or a fungal species [6]? These tests would be even more powerful if they could determine which species (from a selected list) is present, and indeed, investigators have recently developed tests that do this. For example, in a single assay, Chakravorty and his colleagues [7] were able to identify which pathogenic or commensal bacterial species was present in a blood sample from a list of 111 species in 64 different genera. Similarly, El-Hajj and her colleagues [8] have developed an assay that distinguishes 27 different species of Mycobacteria. These assays include several molecular beacons labeled with differently colored fluorophores in the same tube. Current instruments are able to distinguish up to seven fluorescent colors in the same tube, which suggests a limit of seven targets. So, to achieve this high level of multiplexing, the assays not only distinguish the fluorescence of each differently colored molecular beacon, they measure the characteristic stability of the probe-target hybrids that each molecular beacon forms by raising the temperature to see when each molecular beacon dissociates from the target (causing a marked decrease in fluorescence). This analysis identifies the target by indicating the relationship of the probe sequence to the target sequence. If the probe is a good match to the target, the probe-target hybrid is quite stable, and this stability is reflected in a high melting temperature, whereas, if the probe is not a good match to the target, the probe-target hybrid is less stable and melts apart at a lower temperature.

Some of these tests can also determine whether the specific pathogen has acquired drug resistance. For example, an assay developed by Alland and colleagues [9-11] for Mycobacterium tuberculosis detects the bacterial RNA polymerase gene with several different molecular beacons that are so specific that the presence of any mutation in the target region causes one of the differently colored molecular beacons not to bind to the target (indicating that the commonly used antibiotic rifampicin will not be able to inhibit the activity of the encoded RNA polymerase). This PCR assay takes only two hours, whereas traditional culture-based tests take at least two weeks.

In a number of clinical situations, it is necessary to detect hundreds or thousands of targets at the same time. For example, such situations occur when the mutations responsible for drug resistance are scattered over long sequence stretches, or can be present on multiple genes. To probe for a large number of mutations, new assay formats are under development that simultaneously screen genomes with thousands of molecular beacons. In these formats, different molecular beacons are immobilized at different locations of a planner array [12], on the surface of beads trapped in microfluidic chambers [13], or on different locations of nanowires [14]. The locations that become fluorescent indicate which mutations are present.

It is not always necessary to amplify nucleic acid to detect a pathogen. Molecular beacons complementary to species-specific regions of ribosomal RNA can be used to identify bacterial and fungal pathogens by in situ hybridization. In novel "molecular blood culture" assays, pathogens are grown for a short period and then...
identified by \textit{in situ} hybridization with molecular beacons, followed by imaging [15].

In addition to their main attribute (that they generate signals without having to separate probe target-hybrids from excess probes, thereby enabling sealed-tube assays), molecular beacons also introduced several design principles that have inspired the development of other kinds of probes. Among these are the use of non-fluorescent dyes as quenchers of fluorescence, the use of hairpins as a means of keeping fluorophores in close contact with quenchers, and the use of hairpins to increase the specificity of hybridization. A small industry of non-fluorescent quenchers, often called "dark" quenchers, with names such as Eclipse, Iowa Black, Blackberry, and Black Hole Quenchers has been spawned [16]. Dark quenchers afford a larger extent of multiplexing, since they do not crowd the available spectrum by emitting light. A number of novel probe formats that utilize hairpins as their central element have also been introduced. For example, Amplifluor Primers contain a 5\textquoteleft hairpin that possesses a fluorophore and a quencher in close contact, but once the resulting amplicon (a piece of DNA that has been synthesized using amplification techniques) is copied, the fluorophore and quencher are separated, generating a bright fluorescence signal [17]. In another variant, called Scorpion Primers, a molecular beacon is attached at the 5\textquoteleft end of the primer, but in this case, it cannot be copied. However, the molecular beacon is designed to bind to a segment of the amplified DNA. Since the probe and the target are now in the same molecule, the molecular beacon can come around and bind to the target. This intramolecular interaction happens more readily than the intermolecular binding of a normal molecular beacon [18].

\textbf{Future directions}

Recent years have seen a wave of technical advances that have begun to realize the potential of molecular beacons to test for diverse human pathogens in clinical diagnostic laboratories, and also food and environmental contaminants. These include new techniques with the ability to test for, and quantify, multiple pathogens in the same

\begin{table}[h]
\centering
\begin{tabular}{|l|l|l|}
\hline
\textbf{Organism} & \textbf{Amplification Scheme} & \textbf{References} \\
\hline
\textbf{Human Pathogens} & & \\
HIV & NASBA, PCR & [4,19,20] \\
HTLV & PCR & [4,21] \\
Oncogenic HPV & NASBA, PCR & [22-24] \\
\textit{Mycobacterium tuberculosis} & PCR & [9-11,25] \\
\textit{HMPV} & NASBA & [26] \\
RSV & NASBA, PCR & [27-29] \\
Enterovirus & NASBA & [30,31] \\
Influenza virus & NASBA, PCR & [32,33] \\
\textit{Entamoeba histolytica} & PCR & [34] \\
\textit{Methicillin-resistant Staphylococcus} & PCR & [35-37] \\
Hepatitis B & NASBA, PCR & [38,39] \\
HPIV & NASBA & [40] \\
West Nile virus & NASBA, PCR & [41,42] \\
Candida dubliniensis & PCR & [43] \\
\textit{Scedosporium} & PCR & [44] \\
Pan-bacteria & NASBA, PCR, melting analysis & [6,7] \\
Pan-fungi & NASBA, PCR & [6] \\
27 \textit{Mycobacterial species} & PCR, melting analysis & [8] \\
6 \textit{Pneumonia-causing agents} & PCR & [45] \\
\textit{Chlamyphila pneumoniae} & NASBA & [46] \\
Multiple bacteria in blood stream & PCR & [47] \\
Lyme disease spirochetes & PCR & [48] \\
Plasmodium & NASBA, PCR & [49,50] \\
\hline
\textbf{Food Pathogens} & & \\
Salmonella & PCR & [51] \\
Escherichia coli & NASBA & [52] \\
Listeria & NASBA & [53] \\
8 food pathogens & PCR, melting analysis & [54] \\
\hline
\textbf{Environmental Pathogens} & & \\
Salmonella & PCR & [55] \\
Escherichia coli & PCR & [56] \\
\textit{Baylisascaris procyonis} & PCR & [57] \\
\textit{Vibrio cholerae} & NASBA, PCR & [58,59] \\
\textit{Bacillus anthracis} & PCR & [60] \\
\hline
\end{tabular}
\caption{Molecular beacon-based assays for pathogens}
\end{table}

Abbreviations: HMPV, \textit{human metapneumovirus}; HPIV, \textit{human parainfluenza virus}; RSV, \textit{respiratory syncytial virus}. 

\pagebreak
clinical sample, and to detect antibiotic resistant strains within hours.

As molecular beacons and allied technologies are adopted in the clinical diagnostics industry, physicians will be able to diagnose diseases with greater precision than ever before.

**Abbreviations**

NASBA, nucleic acid sequence-based amplification; PCR, polymerase chain reaction.

**Competing interest**

The authors are inventors of molecular beacons technology, which is patented and licensed non-exclusively to more than 70 licensees, and the authors receive a portion of the resulting licensing income, both personally, and as unrestricted funds that support ongoing research in their laboratory.

**Acknowledgements**

This work is supported by the National Institutes of Mental Health Grant 079197.

**References**

1. Tyagi S, Kramer FR: *Molecular beacons: probes that fluoresce upon hybridization*. Nat Biotechnol 1996, 14:303-8.

2. Tyagi S, Bratu DP, Kramer FR: *Multicolor molecular beacons for allele discrimination*. Nat Biotechnol 1998, 16:49-53.

3. Leone G, van Schijndel H, van Gemen B, Kramer FR, Schoen CD: *Molecular beacon probes combined with amplification by NASBA enable homogeneous, real-time detection of RNA*. Nucleic Acids Res 1998, 26:2150-5.

4. Vet JA, Majithia AR, Marras SA, Tyagi S, Dube S, Poiesz BJ, Kramer FR: *Multiplex detection of four pathogenic retroviruses using molecular beacons*. Proc Natl Acad Sci U S A 1999, 96:6394-9.

5. Heid CA, Stevens J, Livak KJ, Williams PM: *Real time quantitative PCR*. Genome Res 1996, 6:986-94.

6. Zhao Y, Park S, Kreiswirth BN, Ginocchio CC, Veyret R, Layyoun A, Troesch A, Perlin DS: *Rapid real-time nucleic acid sequence-based amplification-molecular beacon platform to detect fungal and bacterial bloodstream infections*. J Clin Microbiol 2009, 47:2067-78.

7. Chakravorty S, Aladegbami B, Burday M, Levi M, Marras SA, Shah D, El-Hajj HH, Kramer FR, Alland D: *Rapid universal identification of bacterial pathogens from clinical cultures by using a novel sloppy molecular beacon melting temperature signature technique*. J Clin Microbiol 2010, 48:258-67.

8. El-Hajj HH, Marras SA, Tyagi S, Shashkina E, Kamboj M, Kiern TE, Glickman MS, Kramer FR, Alland D: *Use of sloppy molecular beacon probes for identification of mycobacterial species*. J Clin Microbiol 2009, 47:1190-8.

9. Boehme CC, Nabet P, Hillemann D, Nicol MP, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, Milovic A, Jones M, O’Brien SM, Persing DH, Rueck-Gerdes S, Getuzzo E, Rodrigues C, Alland D, Perkins MD: *Rapid molecular detection of tuberculosis and rifampin resistance*. N Engl J Med 2010, 363:1005-15.

10. El-Hajj HH, Marras SA, Tyagi S, Kramer FR, Alland D: *Detection of rifampin resistance in Mycobacterium tuberculosis in a single tube with molecular beacons*. J Clin Microbiol 2001, 39:4131-7.

11. Platek AS, Tyagi S, Pol AC, Telentel A, Miller LP, Kramer FR, Alland D: *Molecular beacon sequence analysis for detecting drug resistance in Mycobacterium tuberculosis*. Nat Biotechnol 1998, 16:359-63.

12. Situma C, Moehring AJ, Noor MA, Soper SA: *Immobilized molecular beacons: a new strategy using UV-activated poly (methyl methacrylate) surfaces to provide large fluorescence sensitivities for reporting on molecular association events*. Anal Biochem 2007, 363:35-48.

13. Zuo X, Yang X, Wang K, Tan W, Wen J: *A novel sandwich assay with molecular beacon as report probe for nucleic acids detection on one-dimensional microfluidic beads array*. Anal Chim Acta 2007, 587:9-13.

14. Stoermer RL, Cederquist KB, McFarland SK, Sha MY, Penn SG, Keating CD: *Coupling molecular beacons to barcoded metal nanowires for multiplexed, sealed chamber DNA bioassays*. J Am Chem Soc 2006, 128:16892-903.

15. [http://miacom-diagnostics.com]

16. Marras SA: *Interactive fluorophore and quencher pairs for labeling fluorescent nucleic acid hybridization probes*. Mol Biotechnol 2008, 38:247-55.

17. Nazarenko IA, Bhattacharj SK, Hofman RJ: *A closed tube format for amplification and detection of DNA based on energy transfer*. Nucleic Acids Res 1997, 25:2516-21.

18. Whitcombe D, Theaker J, Guy SP, Brown T, Little S: *Detection of PCR products using self-probing ampiclons and fluorescence*. Nat Biotechnol 1999, 17:804-7.

19. McIlernon DR, Vavro C, St Clair M: *Evaluation of a real-time nucleic acid sequence-based amplification assay using molecular beacons for detection of human immunodeficiency virus type 1*. J Clin Microbiol 2006, 44:2280-2.

20. Demetriou VL, van de Vijver DA, Kousiappa I, Balotta C, Clotet B, Grossman Z, Jørgensen LB, Lepej SZ, Levy I, Nielsen C, Paraskevis D, van Laethem K, Vandamme AM, Gorbitz BJ, Vercouteren J, Kostrakis LG: *Cellular HIV-1 DNA levels in drug sensitive strains are equivalent to those in drug resistant strains in newly-diagnosed patients in Europe*. PloS One 2010, 5:e10976.

21. Besson G, Kazanji M: *One-step, multiplex, real-time PCR assay with molecular beacon probes for simultaneous detection,
differentiation, and quantification of human T-cell leukemia virus types 1, 2, and 3. J Clin Microbiol 2009, 47:1129-35.

F1000 Factor 6
Evaluated by Sanjay Tyaji 23 Apr 2012

22. Molden T, Kraus I, Skomedal H, Nordstrom T, Karlson F: PreTect HPV-Proofer: real-time detection and typing of E6/E7 mRNA from carcinogenic human papillomaviruses. J Virol Methods 2007, 142:204-12.

F1000 Factor 6
Evaluated by Sanjay Tyaji 23 Apr 2012

23. Ratnam S, Coutlee F, Fontaine D, Bentley J, Escott N, Ghatage P, Gadag V, Holloway G, Bartellia E, Kum N, Giede C, Lear A: Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer. J Clin Microbiol 2010, 48:2779-85.

F1000 Factor 6
Evaluated by Sanjay Tyaji 23 Apr 2012

24. Kumar P, Nath K, Rath B, Sen MK, Vishalakshi P, Chauhan DS, Takacs T, Jeney C, Kovacs L, Mozes J, Benczik M, Sebe A: Molecular beacon-based real-time PCR method for detection of 15 high-risk and 5 low-risk HPV types. J Virol Methods 2008, 149:133-62.

F1000 Factor 6
Evaluated by Sanjay Tyaji 23 Apr 2012

25. Moran JR, Lotlikar M, Zhang F, Gineo CC: Clinical evaluation of NucliSENs magnetic extraction and NucliSENs analyte-specific reagents for real-time detection of human metapneumovirus in pediatric respiratory specimens. J Clin Microbiol 2008, 46:1274-80.

F1000 Factor 6
Evaluated by Sanjay Tyaji 23 Apr 2012

26. Deiman B, Schrover C, Moore C, Westmoreland D, van de Wiel P: Rapid and highly sensitive qualitative real-time assay for detection of respiratory syncytial virus (RSV) in paediatric respiratory specimens. J Pathol 2009, 211:403-8.

F1000 Factor 6
Evaluated by Sanjay Tyaji 23 Apr 2012

27. Manji R, Lotlikar M, Zhang F, Gineo CC: Clinical evaluation of NucliSSEN magnetic extraction and NucliSSEN analyte-specific reagents for real-time detection of respiratory syncytial virus (RSV) in paediatric respiratory specimens. J Clin Pathol 2009, 62:998-1002.

F1000 Factor 6
Evaluated by Sanjay Tyaji 23 Apr 2012

28. Deiman B, Schrover C, Moore C, Westmoreland D, van de Wiel P: Rapid and highly sensitive qualitative real-time assay for detection of respiratory syncytial virus A and B using NASBA and molecular beacon technology. J Virol Methods 2007, 146:29-35.

F1000 Factor 6
Evaluated by Sanjay Tyaji 23 Apr 2012

29. O'Shea MK, Ryan MA, Hawksworth AW, Alsip BJ, Gray GC: Symptomatic respiratory syncytial virus infection in previously healthy young adults living in a crowded military environment. Clin Infect Dis 2005, 41:311-17.

F1000 Factor 6
Evaluated by Sanjay Tyaji 23 Apr 2012

30. Landry ML, Garner R, Ferguson D: Real-time nucleic acid sequence-based amplification using molecular beacons for detection of enterovirus RNA in clinical specimens. J Clin Microbiol 2005, 43:3136-9.

F1000 Factor 6
Evaluated by Sanjay Tyaji 23 Apr 2012

31. Capua SE, Gorgievski-Hrisoho M: Detection of enterovirus RNA in cerebrospinal fluid (CSF) using NucliSens EasyQ Enterovirus assay. J Clin Virol 2005, 32:236-40.

F1000 Factor 6
Evaluated by Sanjay Tyaji 23 Apr 2012

32. Muradrasoli S, Mohamed N, Belak S, Cizfrira G, Herrmann B, Berencsi G, Blumberg J: Broadly targeted triplex real-time PCR detection of influenza A, B and C viruses based on the nucleoprotein gene and a novel “MegaBeacon” probe strategy. J Virol Methods 2010, 163:313-22.

F1000 Factor 6
Evaluated by Sanjay Tyaji 23 Apr 2012

33. Moore C, Hibbits S, Owen N, Corden SA, Harrison G, Fox J, Gelder C, Westmoreland D: Development and evaluation of a real-time nucleic acid sequence based amplification assay for rapid detection of influenza A. J Med Virol 2004, 74:619-28.

F1000 Factor 6
Evaluated by Sanjay Tyaji 23 Apr 2012

34. Roy S, Kabir M, Mondal D, Ali IK, Petri WA Jr., Haque R: Real-time-PCR assay for diagnosis of Entamoeba histolytica infection. J Clin Microbiol 2005, 43:2168-72.

F1000 Factor 6
Evaluated by Sanjay Tyaji 23 Apr 2012

35. Warren DK, Liao RS, Merz LR, Eveland M, Dunne WM Jr: Detection of methicillin-resistant Staphylococcus aureus directly from nasal swab specimens by a real-time PCR assay. J Clin Microbiol 2004, 42:5578-81.

F1000 Factor 6
Evaluated by Sanjay Tyaji 23 Apr 2012

36. Huletsky A, Giroux B, Rossbach V, Gagnon M, Vaillancourt C, Bernard M, Gagnon F, Truchon K, Bastien M, Picard FJ, van Belkum A, Ouellette M, Roy PH, Bergeron MG: New real-time PCR assay for rapid detection of methicillin-resistant Staphylococcus aureus directly from specimens containing a mixture of staphylococci. J Clin Microbiol 2004, 42:1875-84.

F1000 Factor 6
Evaluated by Sanjay Tyaji 23 Apr 2012

37. Sinisimer D, Leekha S, Park S, Marras SA, Koreen L, Willey B, Naidsch S, Mussa KA, Kreiswirth BN: Use of a multiplex molecular beacon platform for rapid detection of methicillin and vancomycin resistance in Staphylococcus aureus. J Clin Microbiol 2005, 43:4585-91.

F1000 Factor 6
Evaluated by Sanjay Tyaji 23 Apr 2012

38. Sum SS, Wong DK, Yuen MF, Yuan HJ, Yu J, Lai CL, Ho D, Zhang L: Real-time PCR assay using molecular beacon for quantitation of hepatitis B virus DNA. J Clin Microbiol 2004, 42:3438-40.

F1000 Factor 6
Evaluated by Sanjay Tyaji 23 Apr 2012

39. Yates S, Penning M, Gouldsmit J, Frantzen I, van de Weijer B, van Strijp D, van Gemen B: Quantitative detection of hepatitis B virus DNA by real-time nucleic acid sequence-based amplification with molecular beacon detection. J Clin Microbiol 2001, 39:3656-65.

F1000 Factor 6
Evaluated by Sanjay Tyaji 23 Apr 2012

40. Hibbritts S, Rahman A, John R, Westmoreland D, Fox JD: Development and evaluation of NucliSens basic kit NASBA for diagnosis of parainfluenza virus infection with ‘end-point’ and ‘real-time’ detection. J Virol Methods 2003, 108:145-55.

F1000 Factor 6
Evaluated by Sanjay Tyaji 23 Apr 2012

41. Lanciotto RS, Kerst AJ: Nucleic acid sequence-based amplification assays for rapid detection of West Nile and St. Louis encephalitis viruses. J Clin Microbiol 2001, 39:4506-13.

F1000 Factor 6
Evaluated by Sanjay Tyaji 23 Apr 2012

42. Lee DH, Mathew J, Pfisher W, Ma D, Valinsky J, Prince AM, Andrus L: Individual donor nucleic acid amplification testing for detection of West Nile virus. J Clin Microbiol 2005, 43:5111-6.

F1000 Factor 6
Evaluated by Sanjay Tyaji 23 Apr 2012

43. Park S, Wong M, Marras SA, Cross EW, Kiehn TE, Chaturvedi V, Tyagi S, Perlin DS: Rapid identification of Candida dubliniensis using a species-specific molecular beacon. J Clin Microbiol 2000, 38:2829-36.

F1000 Factor 6
Evaluated by Sanjay Tyaji 23 Apr 2012

44. Castelli MV, Buitrago MJ, Bernai-Martinez L, Gomez-Lopez A, Rodriguez-Tudela JL, Cuenca-Estrella M: Development and validation of a quantitative PCR assay for diagnosis of scedosporiosis. J Clin Microbiol 2008, 46:3412-6.

F1000 Factor 6
Evaluated by Sanjay Tyaji 23 Apr 2012

45. Morozumi M, Nakayama E, Izawa S, Aski Y, Hasagawa K, Kobayashi R, Chiba N, Tajima T, Uebukata K: Simultaneous detection of pathogens in clinical samples from patients with community-acquired
pneumonia by real-time PCR with pathogen-specific molecular beacon probes. J Clin Microbiol 2006, 44:1440-6.

46. Loens K, Beck T, Goossens H, Ursi D, Overdijk M, Sillekens P, leven M: Development of conventional and real-time nucleic acid sequence-based amplification assays for detection of Chlamydia pneumoniae in respiratory specimens. J Clin Microbiol 2006, 44:1241-4.

47. Chiba N, Murayama SY, Morozumi M, Nakayama E, Okada T, Iwata S, Sunakawa K, Ubukata K: Rapid detection of eight causative pathogens for the diagnosis of bacterial meningitis by real-time PCR. J Infect Chemother 2009, 15:92-8.

48. Saidac DS, Marras SA, Parveen N: Detection and quantification of Lyme spirochetes using sensitive and specific molecular beacon probes. BMC Microbiol 2009, 9:43.

49. Elsayed S, Plewes K, Church D, Chow B, Zhang K: Use of molecular beacon probes for real-time PCR detection of Plasmodium falciparum and other plasmodium species in peripheral blood specimens. J Clin Microbiol 2006, 44:622-4.

50. Schneider P, Wolters L, Schoone G, Schallig H, Sillekens P, Hermens R, Sauerwein R: Real-time nucleic acid sequence-based amplification is more convenient than real-time PCR for quantification of Plasmodium falciparum. J Clin Microbiol 2005, 43:402-5.